A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study*†‡*Supported by Sandoz Pharma, Ltd.†Presented in part at the Joint Meeting of the European Society of Human Reproduction and Embryology and the European Sterility Congress Organization, Milan, Italy, August 31, 1990.‡The following investigators were participants in this French multicenter study: Philippe Jaquet, M.D., Marseille; Jean-Pierre Louvet, M.D., Toulouse; Didier Dewailly, M.D., Lille; Patrick Roger, M.D., Bordeaux; Jean-Louis Schlienger, M.D., Strasbourg; Gèrard Schaison, M.D., Paris; Pierre Hartemann, M.D., Nancy.

1992 ◽  
Vol 57 (1) ◽  
pp. 74-80 ◽  
Author(s):  
Thierry Brue ◽  
Ioana Lancranjan ◽  
Jean-Pierre Louvet ◽  
Didier Dewailly ◽  
Patrick Roger ◽  
...  
Keyword(s):  
Multicenter Study ◽  
European Society ◽  
Term Treatment ◽  
Human Reproduction ◽  
Joint Meeting ◽  
Long Term Treatment ◽  
Congress Organization ◽  
Long Acting

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

2004 ◽  
Vol 16 (6) ◽  
pp. 319-325 ◽  
Author(s):  
Pierre S. Chue ◽  
Peter D'Hoore ◽  
J. Michael Ramstack
Keyword(s):  
Antipsychotic Agents ◽  
Term Treatment ◽  
Treatment Programs ◽  
Sustained Drug Delivery ◽  
Partial Compliance ◽  
Long Term Treatment ◽  
Optimal Maintenance ◽  
Long Acting ◽  
The Impact

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.

Long-term treatment of refractory neonatal hypoglycemia with long-acting somatostatin analog

1987 ◽  
Vol 111 (4) ◽  
pp. 548-551 ◽  
Author(s):  
Jeffrey A. Jackson ◽  
Henry B. Hahn ◽  
Charles E. Oltorf ◽  
Thomas M. O'Dorisio ◽  
Arthur I. Vinik
Keyword(s):  
Term Treatment ◽  
Somatostatin Analog ◽  
Neonatal Hypoglycemia ◽  
Long Term Treatment ◽  
Long Acting

The Role of Long Acting Antipsychotics in Bipolar Disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. S15-S15
Author(s):  
E. Vieta
Keyword(s):  
Bipolar Disorder ◽  
Meta Analysis ◽  
Term Treatment ◽  
Patient Profile ◽  
Long Term Treatment ◽  
Short And Long Term ◽  
Competing Interest ◽  
Long Acting

Antipsychotics are widely used for the short and long-term treatment of bipolar disorder. Depot and long-acting injectable formulations (LAIs) can be particularly useful for certain subgroups of patients. This lecture will discuss the available data from randomized controlled trials of LAIs in bipolar disorder. A recently published meta-analysis and individual studies assessing depot medications, as well as modern LAIs such as risperidone, paliperidone and aripiprazole, will be reviewed, looking carefully into the prevention of either pole of illness and tolerability. Potential indications and patient profile, based on data and clinical experience, will be discussed.Disclosure of interestThe author has not supplied his declaration of competing interest.

scholarly journals LONG TERM TREATMENT BY A LONG ACTING SOMATOSTATIN ANALOGUE (SMS 201–995) IN A 4 MONTHS BOY PRESENTING WITH PRIMARY PERMANENT HYPERINSULINISM

1988 ◽  
Vol 23 (1) ◽  
pp. 135-135 ◽  
Author(s):  
M T Tauber ◽  
J P Tauber ◽  
A G Harris ◽  
J M Lafitte ◽  
M Keddari ◽  
...  
Keyword(s):  
Term Treatment ◽  
Somatostatin Analogue ◽  
Long Term Treatment ◽  
Long Acting

Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment

CNS Spectrums ◽  
2012 ◽  
Vol 17 (s1) ◽  
pp. 10-21 ◽  
Author(s):  
Debbi A. Morrissette ◽  
Stephen M. Stahl
Keyword(s):  
Term Treatment ◽  
Depot Antipsychotic ◽  
Long Term Treatment ◽  
Therapeutic Results ◽  
Potential Benefits ◽  
Long Acting

Antipsychotics are the mainstay of treatment for patients with schizophrenia. However, these medications only work if they are taken and perhaps work best if they are taken for longer periods of time than seen in typical research trials. Here we explore the idea of “time as a drug” by reviewing the data showing the potential benefits of long-term antipsychotic use. We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results.

Sign in / Sign up

Export Citation Format

Share Document